HC Wainwright Reaffirms “Neutral” Rating for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $3.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 54.64% from the company’s previous close.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $12.20.

Inovio Pharmaceuticals Stock Performance

INO opened at $1.94 on Wednesday. The company has a fifty day moving average price of $2.04 and a two-hundred day moving average price of $3.74. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75. The firm has a market capitalization of $50.63 million, a PE ratio of -0.92 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million. Equities analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Alpine Global Management LLC acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at $31,000. Stonepine Capital Management LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $1,922,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $412,000. Graham Capital Management L.P. bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $114,000. Finally, Deutsche Bank AG lifted its position in Inovio Pharmaceuticals by 524.6% in the 4th quarter. Deutsche Bank AG now owns 89,864 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 75,477 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.